Skip to main content
OpenTrials
Completed

NCT Number: NCT05057299

Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes

Patients with extramedullary leukemia were identified over 10 years (January 2003 to September 2019). Clinicopathological,genetic-molecular features were identified and survival outcomes were studied and analyzed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myeloid Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Sarcoma Sarcoma, Myeloid

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

King Hussein Cancer Center

Amman, 11941, Jordan

About this study

We retrospectively collected patients demographics ,including clinicopathological and genetic-molecular parameters in patients with extramedullary leukemia between January 2003 till September 2019 from King Hussein cancer center(KHCC) electronic medical records. All potential prognostic factors were identified and compared with worldwide data published previously. Treatment and survival outcomes were studies and analyzed.

Primary endpoint : Overall survival (OS).

Secondary endpoint :

  • Progression Free Survival (PFS).
  • incidence of extramedullary leukemia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult subjects aged ≥18 year and up to 75 years
  • Male and females.
  • Initially diagnosed and treated with extramedullary leukemia at KHCC and followed till last encounter.
  • Patients, who underwent an allogeneic stem cell transplant.
  • Period January 2003-September 2019

Exclusion criteria

  • Pediatric patients <18 year of age
  • Patients, who lost their follow up within study period.

Treatment and study plan

retrospective data analysis

Other

chart review, analysis and reporting outcomes

Primary outcomes

  1. Overall survival (OS),

    Time frame: "4 year, year 4"

    To calculate the median and estimated 4-year overall survival

Secondary outcomes

  1. Progression-Free Survival

    Time frame: "4 year, year 4"

    To calculate the median and estimated 4-year PFS

Sponsors and collaborators

Lead sponsor

King Hussein Cancer Center

Other

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Sep 27, 2021
Registry last updated
Sep 27, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.